-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
With the advancement of medical reform policies, the pharmaceutical industry is accelerating changes.
In this context, it is no longer uncommon for pharmaceutical company executives to change frequently, and there are even some cases that are optimistic about the future of Chinese innovative pharmaceutical companies, from multinational pharmaceutical companies to local pharmaceutical companies
.
Recently, it was reported that Du Haochen, vice president of AstraZeneca China and head of the county business department, decided to leave the company due to personal reasons.
The term of office will officially end on November 17, 2021
.
According to other news, from November 18, 2021, Du Haochen will formally join BeiGene as the head of the broad market, based in Shanghai
.
According to the data, Du Haochen is currently the vice president of AstraZeneca China and the head of the county business department.
He was in charge of business and county market at Pfizer for many years.
From 2010 to 2015, Du Haochen served as the deputy director of Pfizer China's county sales, and he built it in one hand.
He joined Pfizer’s national county hospital sales team and achieved outstanding results; in 2015, Du Haochen left Pfizer to join AstraZeneca as the national head of the county business department, set up and led AstraZeneca and county teams, and implemented AZ expansion Sinking strategy, and seeking business innovation and breakthroughs, has made a great contribution to the expansion of AstraZeneca's business map to the grassroots market
.
BeiGene was one of the domestic innovative drug companies that established a full-time team to cover a broad market of innovative oncology drugs.
In 2020, BeiGene officially launched a broad market team plan.
The products it is responsible for include PD-1 tislelizumab, BTK inhibitors zebutinib, disulimab, lenalidomide and other major new products on the market, and with the increase of BeiGene's commercial products, the industry expects that the company will need more products to come from the market.
Promotion
.
It is worth mentioning that in the past two months, AstraZeneca has had four senior executives resigned, and there are many cases where senior executives joined Chinese pharmaceutical companies after they resigned
.
Among them, He Yimin, Assistant Vice President of Digestion and Respiratory Atomization Business Department of AstraZeneca China, decided to leave the company in order to seek external career development opportunities.
The term of office will officially end on November 15, 2021..
On October 18, he joined Roche as the person in charge of the treatment of gastrointestinal tumors; at the end of July this year, Dong Lijun, the former general manager of AstraZeneca China’s digestion and product development business department announced his resignation, and joined Luoxin Pharmaceutical in August.
Served as Deputy General Manager and at the same time as the company’s Executive Vice President and Chief Operating Officer (COO); on August 3, AstraZeneca China announced to employees that Xu Jing, the company’s vice president and head of the Digitalization and Business Innovation Department, decided to find an external career Development opportunities; On September 22, AstraZeneca’s former Eastern RGM and Chairman of the Sales Advisory Committee, Zhang Anwei, resigned, and subsequently joined Luo Xin as the general manager of sales of innovative drugs and the group vice president
.
Behind the resignation of senior executives of multinational pharmaceutical companies to join local pharmaceutical companies, industry adjustments are accelerating and market competition is becoming more intense
.
According to relevant statistics, 30% of the R&D talents resigned by multinational pharmaceutical companies in 2020 will join local pharmaceutical companies and biotech companies.
This proportion has doubled from 15% in 2017
.
Judging from the employment situation, most of the executives of multinational pharmaceutical companies have entered local innovative drug companies after leaving their posts.
This shows that the rapid development and rise of domestic innovative pharmaceutical companies has attracted the presence of senior executives of multinational pharmaceutical companies with mature experience
.
The industry expects that with the changes in the industrial structure and market share, the talent flow of multinational pharmaceutical companies will continue in the future, and the pattern distribution between the two will continue to be rewritten
.
In this context, it is no longer uncommon for pharmaceutical company executives to change frequently, and there are even some cases that are optimistic about the future of Chinese innovative pharmaceutical companies, from multinational pharmaceutical companies to local pharmaceutical companies
.
Recently, it was reported that Du Haochen, vice president of AstraZeneca China and head of the county business department, decided to leave the company due to personal reasons.
The term of office will officially end on November 17, 2021
.
According to other news, from November 18, 2021, Du Haochen will formally join BeiGene as the head of the broad market, based in Shanghai
.
According to the data, Du Haochen is currently the vice president of AstraZeneca China and the head of the county business department.
He was in charge of business and county market at Pfizer for many years.
From 2010 to 2015, Du Haochen served as the deputy director of Pfizer China's county sales, and he built it in one hand.
He joined Pfizer’s national county hospital sales team and achieved outstanding results; in 2015, Du Haochen left Pfizer to join AstraZeneca as the national head of the county business department, set up and led AstraZeneca and county teams, and implemented AZ expansion Sinking strategy, and seeking business innovation and breakthroughs, has made a great contribution to the expansion of AstraZeneca's business map to the grassroots market
.
BeiGene was one of the domestic innovative drug companies that established a full-time team to cover a broad market of innovative oncology drugs.
In 2020, BeiGene officially launched a broad market team plan.
The products it is responsible for include PD-1 tislelizumab, BTK inhibitors zebutinib, disulimab, lenalidomide and other major new products on the market, and with the increase of BeiGene's commercial products, the industry expects that the company will need more products to come from the market.
Promotion
.
It is worth mentioning that in the past two months, AstraZeneca has had four senior executives resigned, and there are many cases where senior executives joined Chinese pharmaceutical companies after they resigned
.
Among them, He Yimin, Assistant Vice President of Digestion and Respiratory Atomization Business Department of AstraZeneca China, decided to leave the company in order to seek external career development opportunities.
The term of office will officially end on November 15, 2021..
On October 18, he joined Roche as the person in charge of the treatment of gastrointestinal tumors; at the end of July this year, Dong Lijun, the former general manager of AstraZeneca China’s digestion and product development business department announced his resignation, and joined Luoxin Pharmaceutical in August.
Served as Deputy General Manager and at the same time as the company’s Executive Vice President and Chief Operating Officer (COO); on August 3, AstraZeneca China announced to employees that Xu Jing, the company’s vice president and head of the Digitalization and Business Innovation Department, decided to find an external career Development opportunities; On September 22, AstraZeneca’s former Eastern RGM and Chairman of the Sales Advisory Committee, Zhang Anwei, resigned, and subsequently joined Luo Xin as the general manager of sales of innovative drugs and the group vice president
.
Behind the resignation of senior executives of multinational pharmaceutical companies to join local pharmaceutical companies, industry adjustments are accelerating and market competition is becoming more intense
.
According to relevant statistics, 30% of the R&D talents resigned by multinational pharmaceutical companies in 2020 will join local pharmaceutical companies and biotech companies.
This proportion has doubled from 15% in 2017
.
Judging from the employment situation, most of the executives of multinational pharmaceutical companies have entered local innovative drug companies after leaving their posts.
This shows that the rapid development and rise of domestic innovative pharmaceutical companies has attracted the presence of senior executives of multinational pharmaceutical companies with mature experience
.
The industry expects that with the changes in the industrial structure and market share, the talent flow of multinational pharmaceutical companies will continue in the future, and the pattern distribution between the two will continue to be rewritten
.
